I've been reading up on small intestinal bacterial overgrowth (SIBO) because it's linked to rosacea and IBS -- two conditions that I have.
I just found this, and want to share it with you guys:
https://www1.uegw.org/guest/ID90f7a8...iew?ABSID=3249
Edit: If you're wondering where this is from, it's the United European Gastroenterology Week website.
I just found this, and want to share it with you guys:
https://www1.uegw.org/guest/ID90f7a8...iew?ABSID=3249
INTRODUCTION: Several pathogenetic factors have been implicated in the development of rosacea, but the role of intestinal bacteria has never been investigated.
AIMS & METHODS: We aimed at assessing the presence of small intestinal bacterial overgrowth (SIBO) in patients with rosacea and the clinical effectiveness of its eradication.We enrolled 60 consecutive rosacea patients (43 females, 17 males; mean age 52 ± 15) and 60 healthy controls, sex- and age-matched. All patients and controls underwent lactulose and glucose breath tests (BTs), in order to assess the presence of SIBO. Patients positive for SIBO were randomized to receive rifaximin 1200 mg/die for 10 days or placebo.Eradication was assessed with the same BTs after one month of the end of antibiotic therapy. Two independent dermatologists evaluated clinical features of rosacea before and after treatment on the basis of an objective scale.
RESULTS: We found an increased prevalence of SIBO in patients with rosacea compared to controls (40/60 vs 3/60, respectively, p<0.001). Oro-cecal transit time resulted significantly delayed in patients with SIBO than in controls (p<0.01). After SIBO eradication we obtained a complete recovery of cutaneous lesions in 17/20 (85%) and a relevant improvement in 2/20 (10%) patients, while those treated with placebo remained unchanged (14/16) or even worsened (2/16), (p<0,001). These latter patients were subsequently switched to rifaximin therapy with complete resolution of rosacea in 14/16 and significant improvement in the remaining 2 cases.
CONCLUSION: Our study shows the high prevalence of SIBO in patients with rosacea and emphasizes the clinical effectiveness of its eradication in inducing almost complete remission of cutaneous lesions.
AIMS & METHODS: We aimed at assessing the presence of small intestinal bacterial overgrowth (SIBO) in patients with rosacea and the clinical effectiveness of its eradication.We enrolled 60 consecutive rosacea patients (43 females, 17 males; mean age 52 ± 15) and 60 healthy controls, sex- and age-matched. All patients and controls underwent lactulose and glucose breath tests (BTs), in order to assess the presence of SIBO. Patients positive for SIBO were randomized to receive rifaximin 1200 mg/die for 10 days or placebo.Eradication was assessed with the same BTs after one month of the end of antibiotic therapy. Two independent dermatologists evaluated clinical features of rosacea before and after treatment on the basis of an objective scale.
RESULTS: We found an increased prevalence of SIBO in patients with rosacea compared to controls (40/60 vs 3/60, respectively, p<0.001). Oro-cecal transit time resulted significantly delayed in patients with SIBO than in controls (p<0.01). After SIBO eradication we obtained a complete recovery of cutaneous lesions in 17/20 (85%) and a relevant improvement in 2/20 (10%) patients, while those treated with placebo remained unchanged (14/16) or even worsened (2/16), (p<0,001). These latter patients were subsequently switched to rifaximin therapy with complete resolution of rosacea in 14/16 and significant improvement in the remaining 2 cases.
CONCLUSION: Our study shows the high prevalence of SIBO in patients with rosacea and emphasizes the clinical effectiveness of its eradication in inducing almost complete remission of cutaneous lesions.
Comment